Objective  To fully understand the global patent technology and development status of sacubitril valsartan, and to provide reference for domestic pharmaceutical enterprises to carry out technology research and development, patent layout, market development and policy formulation of cocrystal drugs.

Methods  Based on the IncoPat patent database, the patent literature of sacubitril valsartan in the world in the past 20 years was comprehensively searched, and the quantitative analysis and interpretation were carried out from multiple dimensions such as patent application trend, patent technology source, key applicants, technology field distribution, patent technology development trends of original research enterprises, and key technology branches.

Results  A total of 285 related patents were retrieved and screened. China accounted for 43% of the global patent application for sacubitril valsartan. It was the main source of technological innovation. Its patent applications were currently entering the mature stage. The number of applications ranked first in the original research company Novartis, which focused on the pharmaceutical preparation and preparation process.

Conclusion  The successful development of sacubitril valsartan sodium cocrystal drug has important guidance and reference for the optimization and development of the combined application of the two drugs. The development of drug cocrystals, improved new drugs, and new indications of precision medicine have become research trends and hotspots. Make full use of artificial intelligence technology to enhance the success rate of research and development.

1. 闫贤良, 高玉龙. 陶英沙库巴曲缬沙坦钠在心力衰竭患者中的临床疗效观察[J]. 中国循证心血管医学杂志, 2019, 11(10): 1248-1250, 1254. [Yan XL, Gao YL. Clinical efficacy of valsartan sodium administrated in patients with heart failure[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2019, 11(10): 1248-1250, 1254.] DOI: 10.3969/j.issn.1674-4055.2019.10.24.

2. 李洁, 蒋运兰. 慢性心力衰竭病人衰弱发生率的系统评价 [J]. 循证护理, 2023, 9(6): 951-957. [Li J, Jiang YL. Incidence of frailty in patients with chronic heart failure: a systematic review[J]. Chinese Evidence-Based Nursing, 2023, 9(6): 951-957.] DOI: 10.12102/j.issn.2095-8668.2023.06.001.

3. 王宏亮, 王欢. 首个血管紧张素受体-脑啡肽酶双重抑制剂—entresto（sacubitril/缬沙坦）[J]. 临床药物治疗杂志, 2015, 13(6): 85-88. [Wang HL, Wang H. A First-in-class angiotensin II receptor-neprilysin inhibitor (ARNi) entresto (sacubitril/valsartan)[J]. Clinical Medication Journal, 2015, 13(6): 85-88.] DOI: 10.3969/j.issn.1672-3384.2015.06.021.

4. Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure[J]. Clin Pharmacol Ther, 2013, 94(4): 445-448. DOI: 10.1038/clpt.2013.146.

5. 韩云川, 徐晓宏. 沙库巴曲缬沙坦钠片仿制药药学研究探讨 [J]. 中国临床药理学杂志, 2025, 41(2): 290-295. [Han YC, Xu XH. Discussion on the pharmaceutical research of generic drugs of sacubitril valsartan sodium tablets[J]. The Chinese Journal of Clinical Pharmacology, 2025, 41(2): 290-295.] DOI: 10.13699/j.cnki.1001-6821.2025.02.028.

6. 张三印, 张婷. 基于全基因组泛受体的药靶同筛中药开发与评价新策略[J]. 药学学报, 2025, 60(8): 2375-2388. [Zhang  SY, Zhang T. A novel strategy for development and evaluation of traditional Chinese medicine based on genome-wide pan-receptor drug-target coscreening[J]. Acta Pharmaceutica Sinica, 2025, 60(8): 2375-2388.] DOI: 10.16438/j.0513-4870.2025-0377.

7. Katz ME, Frishman WH, Aronow WS. Aronow. Sacubitril-valsartan (LCZ696) in the treatment of systemic hypertension: an updated review of neprilysin inhibition combined with angiotensin II receptor blockade[J]. Cardio Rev, 2025, 33(5): 437-440. DOI: 10.1097/CRD.0000000000000648.

8. Shaikh TR, George CP, Bhukya P. Novel crystal forms of entresto: a supramolecular complex of trisodium sacubitril/valsartan hemi pentahydrate[J]. CrystEngComm, 2022, 42: 7387. DOI: 10.1039/d2ce01009g.

9. 刘启明. 专利即将到期的重要药品及其仿制药前景分析[J]. 中国发明与专利, 2011, (10): 17-20. [Liu QM. Analysis of the prospects for important drugs with approaching patent expiration and their generic drugs[J]. China Invention & Patent, 2011, (10): 17-20.] DOI: 10.3969/j.issn.1672-6081.2011.10.006.

10. 王雅捷, 汪帆. 小剂量重组人脑利钠肽联合沙库巴曲缬沙坦钠治疗冠心病合并急性心力衰竭的疗效及安全性 [J]. 心血管康复医学杂志, 2025, 34(5): 658-663. [Wang YJ, Wang F. Efficacy and safety of low dose rhBNP combined with sacubitril valsartan sodium in patients with coronary heart disease and acute heart failure[J]. Chinese Journal of Cardiovascular Rehabilitation Medicine, 2025, 34(5): 658-663.] DOI: 10.3969/j.issn.1008-0074.2025.05.12.

11. 中国药典2025年版. 四部[S]. 2025: 511-512.

12. 潘静, 黄晓龙. 药物共晶技术研究进展及药学研究思考 [J]. 中国新药杂志, 2025, 34(5): 477-482. [Pan J, Huang XL. Advancements in pharmaceutical co-crystal research and key considerations[J]. Chinese Journal of New Drugs, 2025, 34(5): 477-482.] DOI: 10.22251/j.cnki.1003-3734.2025.05.005.

13. Guo MS, Sun XJ, Chen JH, et al. Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications[J]. Acta Pharm Sin B, 2021, 11(8): 2537-2564. DOI: 10.1016/j.apsb.2021.03.030.

14. 解晓妮, 赵霞. 药物共晶类专利申请及审查[J]. 中国新药杂志, 2022, 31(20): 1979-1983. [Xie XN, Zhao X. Patent application and examination in pharmaceutical cocrystal field[J]. Chinese Journal of New Drugs, 2022, 31(20): 1979-1983.] DOI: 10.3969/j.issn.1003-3734.2022.20.002.

15. 吕奕, 张怡萌, 茅宁莹. 我国化学药改良型新药申报审批情况分析与思考[J]．中国新药杂志, 2023, 32(15): 1523-1530. [Lyu Y, Zhang YM, Mao NY. Analysis and thinking on the application and approval of improved new chemical drugs in China[J]. Chinese Journal of New Drugs, 2023, 32(15): 1523-1530.] DOI: 10.3969/j.issn.1003-3734.2023.15.006.

16. 李艳丽. 精准医疗背景下中欧给药群体类医药用途发明专利审查比较——以生理指标限定的给药群体为视角[J]. 中国新药杂志, 2026, 35(1): 1-6. [Li YL. Comparison of China-Europe examination of patient-group-specific medical use patents under the background of precision medicine: from the perspective of patient population based on physiological indicators[J]. Chinese Journal of New Drugs, 2026, 35(1): 1-6]. https://link.cnki.net/urlid/11.2850.R.20251114.0816.002.

17. 国家知识产权局. 国家知识产权局无效宣告请求审查决定（第568709号）[EB/OL]. (2025-06-06) [2025-12-19]. https://www.cnipa.gov.cn/module/download/downfile.jsp?classid=0&showname=2-%E7%AC%AC568709%E5%8F%B7%E6%97%A0%E6%95%88%E5%86%B3%E5%AE%9A.pdf&filename=4e9197022bf447a182352bfa41e4214f.pdf.

18. 马骏威, 刘涓, 任连杰. 共晶药物的药学研究思考[J].中国新药杂志, 2025, 34(22): 2366-2371. [Ma JW, Liu J, Ren LJ. Considerations on pharmaceutical research of co-crystal drugs[J]. Chinese Journal of New Drugs, 2025, 34(22): 2366-2371.] DOI: 10.20251/j.cnki.1003-3734.2025.05.005.

19. 张涛, 罗玉, 张旭, 等. 难溶性药物阿瑞匹坦的新剂型和制剂新技术研究进展[J], 药学前沿, 2025, 29(8): 1431-1440. [Zhang T, Luo Y, Zhang X, et al. Research progress on new dosage forms and new technology for the formulation of the insoluble drug aprepitant[J]. Frontiers in Pharmaceutical Sciences, 2025, 29(8): 1431-1440.] DOI: 10.12173/j.issn.2097-4922.202504096.

20. 韩云川, 李飞. 沙库巴曲缬沙坦钠“胶囊剂”介绍及药物研发启示[J], 中国临床药理学杂志, 2025, 41(14): 2095-2100. [Han YC, Li F. Formulation design of sacubitril valsartan sodium "capsules" and drug development implications[J]. The Chinese Journal of Clinical Pharmacology, 2025, 41(14): 2095-2100.] DOI: 10.13699/j.cnki.1001-6821.2025.14.026.